Credit Suisse’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$30M Sell
984,959
-5,422
-0.5% -$182K 0.03% 525
2023
Q4
$35.3M Sell
990,381
-39,942
-4% -$1.49M 0.03% 482
2023
Q3
$45.1M Sell
1,030,323
-102,594
-9% -$5.01M 0.05% 406
2023
Q2
$55.9M Sell
1,132,917
-4,456
-0.4% -$205K 0.06% 368
2023
Q1
$47.1M Buy
1,137,373
+5,627
+0.5% +$233K 0.05% 417
2022
Q4
$50.2M Buy
1,131,746
+12,916
+1% +$539K 0.05% 394
2022
Q3
$43.7M Sell
1,118,830
-975
-0.1% -$44.6K 0.05% 414
2022
Q2
$45.8M Sell
1,119,805
-1,589
-0.1% -$75.3K 0.05% 418
2022
Q1
$73.6M Sell
1,121,394
-90,328
-7% -$5.85M 0.06% 328
2021
Q4
$84.3M Buy
1,211,722
+73,376
+6% +$5.33M 0.04% 433
2021
Q3
$79.2M Sell
1,138,346
-144,111
-11% -$11.1M 0.04% 449
2021
Q2
$102M Sell
1,282,457
-87,409
-6% -$6.35M 0.05% 378
2021
Q1
$89.8M Buy
1,369,866
+312,042
+29% +$19.2M 0.05% 445
2020
Q4
$58.9M Buy
1,057,824
+1,025,105
+3,133% +$44.3M 0.03% 637
2020
Q3
$1.3M Sell
32,719
-3,761
-10% -$159K ﹤0.01% 2738
2020
Q2
$1.64M Buy
36,480
+13,470
+59% +$586K ﹤0.01% 2544
2020
Q1
$772K Sell
23,010
-4,005
-15% -$144K ﹤0.01% 2855
2019
Q4
$879K Sell
27,015
-3,945
-13% -$112K ﹤0.01% 3225
2019
Q3
$771K Buy
30,960
+1,611
+5% +$46K ﹤0.01% 3190
2019
Q2
$877K Buy
29,349
+4,887
+20% +$143K ﹤0.01% 3031
2019
Q1
$656K Sell
24,462
-3,803
-13% -$116K ﹤0.01% 3191
2018
Q4
$865K Buy
28,265
+11,660
+70% +$363K ﹤0.01% 2893
2018
Q3
$581K Sell
16,605
-10,638
-39% -$337K ﹤0.01% 3212
2018
Q2
$737K Sell
27,243
-2,961
-10% -$69.6K ﹤0.01% 3223
2018
Q1
$619K Buy
30,204
+2,172
+8% +$39.2K ﹤0.01% 3251
2017
Q4
$512K Sell
28,032
-10,789
-28% -$214K ﹤0.01% 3427
2017
Q3
$869K Buy
38,821
+21,941
+130% +$496K ﹤0.01% 3197
2017
Q2
$410K Sell
16,880
-1,118
-6% -$23.8K ﹤0.01% 3274
2017
Q1
$345K Sell
17,998
-51,253
-74% -$898K ﹤0.01% 3471
2016
Q4
$1.35M Buy
69,251
+15,608
+29% +$283K ﹤0.01% 2774
2016
Q3
$849K Buy
53,643
+17,846
+50% +$274K ﹤0.01% 3084
2016
Q2
$505K Buy
35,797
+10,807
+43% +$165K ﹤0.01% 3421
2016
Q1
$420K Buy
24,990
+2,905
+13% +$51.1K ﹤0.01% 3345
2015
Q4
$496K Sell
22,085
-593
-3% -$12.2K ﹤0.01% 3388
2015
Q3
$497K Sell
22,678
-14,997
-40% -$375K ﹤0.01% 3390
2015
Q2
$929K Buy
37,675
+9,307
+33% +$208K ﹤0.01% 3246
2015
Q1
$581K Buy
28,368
+13,661
+93% +$265K ﹤0.01% 3441
2014
Q4
$294K Sell
14,707
-10,616
-42% -$182K ﹤0.01% 4064
2014
Q3
$373K Buy
25,323
+3,287
+15% +$52.4K ﹤0.01% 3817
2014
Q2
$405K Sell
22,036
-25,645
-54% -$427K ﹤0.01% 3951
2014
Q1
$896K Buy
47,681
+34,749
+269% +$712K ﹤0.01% 3226
2013
Q4
$241K Buy
+12,932
New +$188K ﹤0.01% 4219

Other funds holding ATRC

Credit Suisse's ATRC Position: Q1 2024 in Review

Credit Suisse reduced its AtriCure (ATRC) stake by 0.55% in Q1 2024, selling an estimated $182K and leaving 984,959 shares worth $30M. The position accounts for 0.03% of the portfolio, ranked #525.

Credit Suisse first reported a position in ATRC in Q4 2013 and has held it in 42 quarters since. The position peaked at $102M in Q2 2021. 224 funds tracked by Wall St. Rank hold ATRC as of Q1 2024.

  • Credit Suisse held 984,959 shares of AtriCure worth $30M as of Q1 2024.
  • Credit Suisse sold 5,422 AtriCure shares in Q1 2024, an estimated $182K.
  • AtriCure made up 0.03% of Credit Suisse's portfolio in Q1 2024, its #525 holding.
  • Credit Suisse first reported a position in AtriCure in Q4 2013 and has held it in 42 quarters since.
  • Credit Suisse's AtriCure position peaked at $102M in Q2 2021.
  • 224 funds tracked by Wall St. Rank held AtriCure as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.